JHJingdong He

Jingdong He

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jingdong He has a total of 24 co-authors. Here are the top co-authors by number of shared publications:

  • Jiani Guo

    Department of Oncology The Affiliated Huaian No.1 People's Hospital of Nanjing Medical University Huaian People's Republic of China

    2 shared publications
  • Chang-Li Zhu

    Department of Medical Oncology, Huai'an First People's Hospital, Nanjing Medical University, Huai'an City, Jiangsu Province, People's Republic of China

    1 shared publication
  • Hong‐Lei Luo

    Department of Radiotherapy, Huai'an First People's Hospital, Nanjing Medical University, Huai'an, Jiangsu, 223300, China

    1 shared publication
  • Jin Li

    Department of Medical Oncology, Huai'an First People's Hospital, Nanjing Medical University, Huai'an City, Jiangsu Province, People's Republic of China

    1 shared publication
  • Jin Li

    Department of Oncology The Affiliated Huaian No.1 People's Hospital of Nanjing Medical University Huaian China

    1 shared publication
  • Jing-Xian Shao

    Department of Medical Oncology, Huai'an First People's Hospital, Nanjing Medical University, Huai'an City, Jiangsu Province, People's Republic of China

    1 shared publication

Latest Publications

  • Open Access

    Effects of SMC1A on immune microenvironment and cancer stem cells in colon adenocarcinoma

    by Jin Li, Qian Zhou, Li Liu, Jingdong He

    Background: Our previous study suggested that SMC1 has significant functions in colorectal cancer (CRC). However, few reports have shown the effects of structural maintenance of chromosomes 1 (SMC1A) on the immune microenvironment and tumor stem cells.Methods: The Cancer Genome Atlas (TCGA) database, CPTAC database, Human Protein Atlas (HPA) database, the Cancer Cell Line Encyclopedia (CCLE) and Tumor Immune Single‐cell Hub were used. Flow cytometry and immunohistochemical analysis were checked for immune infiltration on MC38 mice model. Human CRC tissues were tested with RT‐qPCR.Results: The mRNA and protein levels of SMC1A were increased in colon adenocarcinoma (COAD) samples. SMC1A was associated with DNA activity. Interestingly, SMC1A was highly expressed in many types of immune cells at single‐cell levels. Moreover, the high expression of SMC1A was positively correlated with immune infiltration, and immunohistochemical analysis showed that SMC1A was positively associated with CD45 expression in MC38 mice model. Also, the percentage of IL4+CD4+ T cells (Th2) and FoxP3+CD4+ T cells (Tregs) was significantly higher in the SMC1A overexpression group than in control by flow cytometry assay in vivo. SMC1A expression could affect the proliferation of T cells in the mice model. The mutation and somatic cell copy number variation (SCNV) of SMC1A were also associated with immune cell infiltration. In addition to SMC1A in the “hot” T‐cell inflammatory microenvironment of colon cancer, SMC1A also positively correlates with the immune checkpoint genes CD274, CTLA4, and PDCD1 in colon adenocarcinoma (COAD) samples. Furthermore, we also found that SMC1A plays a positive correlation with the induction of cancer stem cells (CSCs). Our results also showed that miR‐23b‐3p binds SMC1A.Conclusion: SMC1A may be a bidirectional target switch that simultaneously regulates the immune microenvironment and tumor stem cells. Moreover, SMC1A may be a biomarker for the prediction of immune checkpoint inhibitor (ICI) therapy.


  • Aptamer-conjugated and doxorubicin-loaded grapefruit-derived nanovectors for targeted therapy against HER2+ breast cancer

    by Zhuang Tang, Yali Jun, Yanguan Lv, Yunjie Li, Zhen Zhang, Mingyue Tao, Xiaofei Chen, Jingdong He, Li Zhang, Qi-Long Wang

    Increased human epidermal growth factor receptor 2 (HER2) expression is a hallmark of HER2+ breast cancer. HER2 promotes the growth of cancer cells and makes them particularly aggressive. Currently, trastuzumab is the only HER2-targeted therapeutic agent approved by the FDA for HER2-overexpressing breast cancer treatment. However, clinical efficacy of trastuzumab is limited greatly by the occurrence of drug resistance. In this study, an aptamer (HA1) specific for HER2-overexpressing breast cancer cells was selected using Cell-SELEX. This allowed the development of grapefruit-derived nanovectors (GNVs) conjugated with HA1 that targeted specifically HER2+ breast cancer cells. In vitro experiments demonstrated that HA1 effectively promoted the internalization of GNVs into cancer cells and tumor spheroids. In vivo data showed that drug delivery to tumor tissues and antitumor activities were dramatically enhanced by conjugating HA1 with drug-loaded GNVs. This study indicates that aptamers mediating targeted drug delivery by GNVs represent a promising strategy for HER2+ breast cancer therapy.


  • Open Access

    Comprehensive profile of differentially expressed circular RNAs reveals that hsa_circ_0000069 is upregulated and promotes cell proliferation, migration, and invasion in colorectal cancer

    by Jia-Ni Guo, Jin Li, Chang-Li Zhu, Wan-Ting Feng, Jing-Xian Shao, Li Wan, Ming-De Huang, Jing-Dong He

    Background: Nowadays, despite great progress in cancer research, the detailed mechanisms of colorectal cancer (CRC) are still poorly understood. Circular RNAs (circRNAs), a new star of the non-coding RNA network, have been identified as critical regulators in various cancers, including CRC. Methods and results: In this study, by using unsupervised hierarchical clustering analysis, a novel dysregulated circRNA, hsa_circ_0000069, was found. The expression of hsa_circ_0000069 was measured in 30 paired CRC tissues and adjacent noncancerous tissues using quantitative polymerase chain reaction. A high expression of hsa_circ_0000069 was observed in CRC tissues and correlated with patients’ age and tumor, node, metastasis (TNM) stage (P Conclusion: This study’s findings are the first to demonstrate that hsa_circ_0000069, an important regulator in cancer progression, could be a promising target in the diagnosis and therapy in colorectal cancer.


  • Open Access

    AFAP1‐AS1 is upregulated and promotes esophageal squamous cell carcinoma cell proliferation and inhibits cell apoptosis

    by Hong‐Lei Luo, Ming‐De Huang, Jia‐Ni Guo, Rui‐Hua Fan, Xiao‐Tian Xia, Jing‐Dong He, Xiao‐Fei Chen

    Recent findings indicate that long noncoding RNAs (lncRNAs) were dysregulated in many kinds of tumors including esophageal squamous cell carcinoma (ESCC). LncRNA AFAP1‐AS1 was found to be upregulated in hepatocellular carcinoma (HCC), lung cancer, colorectal cancer, esophageal adenocarcinoma (EAC), pancreatic ductal adenocarcinoma, and nasopharyngeal carcinoma, while its clinical value and potential function in ESCC are still unknown. Expression of AFAP1‐AS1 was measured in 65 ESCC tissues and corresponding noncancerous tissues by quantitative real‐time polymerase chain reaction, which revealed that AFAP1‐AS1 expression was markedly elevated in ESCC tissues and significantly associated with advanced TNM stage (P = 0.004) and larger tumor size (P = 0.040). Moreover, by knocking down AFAP1‐AS1 expression in ESCC cells, the proliferation and colony‐forming ability were inhibited and cell apoptosis was induced. Our data indicated the first time that AFAP1‐AS1, a novel oncogene, was remarkably upregulated and played a critical role in the progression of ESCC.